| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||
Total revenues | |||||||||
- | 150 | 0 | - | - | - | - | - | - | - |
Collaboration and research and development revenue | |||||||||
- | - | - | - | - | - | - | - | 100 | - |
Product revenue | |||||||||
- | - | - | - | - | - | - | - | - | 910 |
Grant revenue | |||||||||
- | - | - | 843 | 1,694 | 1,734 | 1,084 | 69 | 12 | 1 |
Collaboration and research and development revenue | |||||||||
- | - | - | - | 250 | - | - | - | - | - |
Total revenues | |||||||||
- | - | - | 843 | 1,944 | 1,734 | 1,084 | 69 | 112 | 911 |
Operating expenses: | |||||||||
Cost of goods sold | |||||||||
- | - | - | - | - | - | - | - | - | 545 |
Research and development | |||||||||
4,658 | 4,327 | 4,237 | 9,477 | 12,382 | 18,277 | 11,277 | 6,592 | 6,414 | 9,766 |
General and administrative | |||||||||
5,024 | 5,371 | 5,254 | 5,516 | 5,732 | 5,894 | 7,781 | 8,580 | 8,833 | 8,538 |
Other restructuring costs | |||||||||
- | - | - | - | - | - | - | - | - | 366 |
Total operating expenses | |||||||||
9,682 | 9,698 | - | 14,993 | 18,114 | 24,171 | 19,058 | 15,172 | 15,247 | 19,215 |
Total operating expenses | |||||||||
- | - | 9,491 | - | - | - | - | - | - | - |
Operating loss | |||||||||
-9,682 | -9,548 | -9,491 | -14,150 | -16,170 | -22,437 | -17,974 | -15,103 | -15,135 | -18,304 |
Other income (expense): | |||||||||
Payment under guarantee | |||||||||
- | - | - | - | - | - | - | - | - | 1,652 |
Change in valuation of financial instruments associated with stock purchase agreement | |||||||||
- | - | - | - | 51 | 342 | 98 | 423 | - | - |
Change in valuation of Economic Rights | |||||||||
- | - | - | - | - | - | -570 | 23 | - | - |
Change in valuation of liabilities measured at fair value | |||||||||
- | - | - | - | - | 20 | - | 51 | -338 | - |
Change in valuation of warrants liability | |||||||||
- | - | - | - | - | - | - | - | - | 299 |
Warrant re-pricing | |||||||||
- | - | - | - | - | - | - | - | - | -44 |
Foreign exchange gains (losses) | |||||||||
101 | -90 | -39 | 273 | -368 | -10 | 62 | 292 | -68 | -144 |
Interest income | |||||||||
224 | 331 | 118 | 37 | 9 | 6 | 13 | 22 | 37 | 102 |
Interest expense | |||||||||
- | - | - | - | - | - | - | - | 43 | 177 |
Other income, net | |||||||||
231 | 682 | 949 | 66 | 94 | 114 | 5,547 | 77 | - | - |
Total other income, net | |||||||||
556 | 923 | 1,028 | 376 | -316 | -212 | 6,094 | -4 | -412 | -2,214 |
Loss before taxes | |||||||||
-9,126 | -8,625 | -8,463 | -13,774 | -16,486 | -22,649 | -11,880 | -15,107 | -15,547 | -20,518 |
Income tax benefit | |||||||||
-1,296 | -1,337 | -993 | -1,983 | -2,144 | -3,243 | -1,670 | -1,351 | -657 | -948 |
Net loss from continuing operations | |||||||||
- | - | - | - | - | -19,406 | -10,210 | -13,756 | -14,890 | - |
Income from discontinued operations | |||||||||
- | - | - | - | - | 29 | 91 | 907 | - | - |
Income tax on discontinued operations | |||||||||
- | - | - | - | - | 10 | 34 | 337 | - | - |
Net income from discontinued operations | |||||||||
- | - | - | - | - | 19 | 57 | 570 | -1,131 | - |
Net loss | |||||||||
-7,830 | -7,288 | -7,470 | -11,791 | -14,342 | -19,387 | -10,153 | -13,186 | -16,021 | -19,570 |
Dividend on convertible exchangeable preferred shares | |||||||||
201 | 201 | 201 | - | - | - | - | - | - | - |
Dividend on convertible exchangeable preferred shares | |||||||||
- | - | - | 200 | 201 | - | - | - | - | - |
Beneficial conversion feature of Series A convertible stock | |||||||||
- | - | 3,638 | 0 | - | - | - | - | - | - |
Conversion of Series A convertible preferred stock | |||||||||
- | - | 3,537 | 0 | - | - | - | - | - | - |
Net loss applicable to common shareholders | |||||||||
-8,031 | -7,489 | -14,846 | -11,991 | - | - | - | - | - | - |
Deemed dividend on convertible exchangeable preferred shares | |||||||||
- | - | - | - | - | 0 | 9,027 | - | 3,515 | - |
Dividend on convertible exchangeable preferred shares | |||||||||
- | - | - | - | - | 200 | 298 | 728 | 167 | 1,228 |
Net loss applicable to common shareholders | |||||||||
- | - | - | - | -14,543 | -19,587 | -19,478 | -13,914 | -19,703 | -20,798 |
Basic and diluted earnings per common share: | |||||||||
Net loss per share, continuing operations - basic and diluted (in dollars per share) | |||||||||
- | - | - | - | - | -0.89 | -1.29 | -1.75 | -3.43 | - |
Net income per share, discontinued operations - basic and diluted (in dollars per share) | |||||||||
- | - | - | - | - | 0.00 | 0.00 | 0.07 | -0.21 | - |
Net loss per share - basic and diluted (in dollars per share) | |||||||||
-0.49 | -0.62 | -1.95 | -3.50 | -5.36 | -0.89 | -1.28 | -1.68 | -3.64 | -0.94 |
Weighted average common shares outstanding - basic and diluted | |||||||||
16,321 | 12,094 | 7,631 | 3,424 | 2,713 | 21,955 | 15,158 | - | - | - |
Basic (in shares) | |||||||||
- | - | - | - | - | - | - | 8,291 | 5,406 | 22,196 |
Collaboration and research and development revenue [Member] | |||||||||
Total revenues | |||||||||
- | 150 | - | - | - | - | - | - | - | - |